Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood thinner stop strokes before they start in heart disease patients?

NCT ID NCT07202897

Prevention Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the blood thinner rivaroxaban can prevent strokes, heart attacks, and death in people with hypertrophic cardiomyopathy (HCM) who have early signs of atrial damage but normal heart rhythm. About 532 adults aged 40-80 with HCM and reduced left atrial strain will be randomly assigned to rivaroxaban or a placebo. The goal is to see if early treatment can reduce serious events before atrial fibrillation develops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 532 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 40 - 80 years of age 2. 50 and 120 kg of weight 3. In sinus rhythm 4. Prior confirmed diagnosis of "primary" hypertrophic cardiomyopathy 5. Left Atrial reservoir strain measured ≤20% (corelab confirmation) 6. Signature of an informed consent 7. Highly effective contraceptive methods for women of childbearing potential from at least 14 days prior to start treatment, throughout the study treatment period, and until at least 4 weeks after the last dose of study medication Exclusion Criteria: 1. Secondary hypertrophic cardiomyopathy (aortic stenosis, hypertension, amyloidosis and all phenocopies…) 2. Signs of heart failure 3. Hospitalization 4. Uncontrolled blood pressure 5. Creatinine clearance \<30 mL/min (Cockcroft) 6. Severe liver dysfunction, cirrhosis Child B or C 7. Any anticoagulation therapy in the 15 days prior to enrollment 8. Any cardiac surgery in the 30 days prior to enrollment 9. Documented atrial arrhythmia 10. Any major bleeding in the 90 days prior to enrollment 11. Need to be on dual antiplatelet therapy (aspirin \>100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel…). 12. Contraindication for a brain magnetic resonance imaging exam 13. Known hypersensitivity or others contraindications to Rivaroxaban (refer to contraindications) 14. Ischemic stroke or intracranial hemorrhage in the 30 days prior to enrollment 15. Active endocarditis at the time of enrollment 16. Concomitant combined strong P-gp and CYP3A4 inducers or inhibitors 17. Active cancer or life expectancy less than 3 years 18. Non-compliant 19. Participation in another interventional clinical trial 20. Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman or planning pregnancy during the study period and minor) 21. Absence of coverage by a social security scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic cardiomyopathy (HCM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertrophic cardiomyopathy (HCM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Höpital la Pitié-Salpétrière

    NOT_YET_RECRUITING

    Paris, France

  • APHM - Hôpital La Timone

    NOT_YET_RECRUITING

    Marseille, France

  • APHP Hopital Européen Georges Pompidou

    NOT_YET_RECRUITING

    Paris, France

  • APHP, Hôpital Lariboisière

    NOT_YET_RECRUITING

    Paris, France

  • CHU Angers

    NOT_YET_RECRUITING

    Angers, France

  • CHU Bordeaux Haut-Levêque

    NOT_YET_RECRUITING

    Bordeaux, France

  • CHU Brest - Hôpital La Cavale Blanche

    NOT_YET_RECRUITING

    Brest, France

  • CHU Caen

    NOT_YET_RECRUITING

    Caen, France

  • CHU Dijon - Hôpital François Mitterrand

    RECRUITING

    Dijon, France

  • CHU Grenoble Alpes

    NOT_YET_RECRUITING

    Grenoble, France

  • CHU Lille

    NOT_YET_RECRUITING

    Lille, France

  • CHU Nancy

    NOT_YET_RECRUITING

    Vandœuvre-lès-Nancy, France

  • CHU Rangueil Toulouse

    NOT_YET_RECRUITING

    Toulouse, France

  • CHU Rennes - Hôpital Pontchaillou

    RECRUITING

    Rennes, France

  • CHU de Nantes -Hôpital Nord Laennec

    NOT_YET_RECRUITING

    Nantes, 44800, France

  • CHU de Rouen

    NOT_YET_RECRUITING

    Rouen, 76000, France

  • CHU de TOURS - HOPITAL TROUSSEAU

    NOT_YET_RECRUITING

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.